Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy

Joyce K Hwang; Neeraj Agarwal; James Brugarolas; Tian Zhang

doi:10.1158/1078-0432.CCR-20-3506

Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy

Clin Cancer Res. 2021 Jan 1;27(1):5-7. doi: 10.1158/1078-0432.CCR-20-3506. Epub 2020 Oct 26.

Authors

Joyce K Hwang¹, Neeraj Agarwal², James Brugarolas³, Tian Zhang^{4

5

6}

Affiliations

¹ Department of Medicine, Duke University, Durham, North Carolina.
² Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
³ Kidney Cancer Program, Department of Medicine, University of Texas-Southwestern, Dallas, Texas.
⁴ Department of Medicine, Duke University, Durham, North Carolina. [email protected].
⁵ Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina.
⁶ Division of Medical Oncology, Department of Medicine, Durham, North Carolina.

Abstract

Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.See related article by Tannir et al., p. 78.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Carcinoma, Renal Cell* / drug therapy
Hippo Signaling Pathway
Humans
Immunotherapy / adverse effects
Ipilimumab
Kidney Neoplasms* / drug therapy
Nivolumab / adverse effects
Protein Serine-Threonine Kinases / genetics
Sunitinib

Substances

Ipilimumab
Nivolumab
Protein Serine-Threonine Kinases
Sunitinib

Grants and funding

P50 CA196516/CA/NCI NIH HHS/United States